The AMDHD2 Knockout Jurkat Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population for the AMDHD2 gene in Jurkat human T lymphocytes. This product contains a heterogeneous pool of cells with targeted disruption of AMDHD2, enabling loss-of-function studies without clonal selection. The polyclonal format avoids biases of single-cell expansion and reflects population-level genetic perturbation relevant to immune cell research.
Jurkat cells, derived from an acute T-cell leukemia patient, are a widely used model for T-cell signaling, immune response, and leukemia biology. They exhibit rapid suspension growth and robust signaling pathways, making them suitable for CRISPR-based gene editing. The leukemic background additionally facilitates investigation of metabolic and glycosylation abnormalities linked to cancer cell phenotypes.
AMDHD2 encodes a putative N-acetylglucosamine-6-phosphate deacetylase that hydrolyzes GlcNAc-6-P to glucosamine-6-P, a precursor for UDP-GlcNAc synthesis in the hexosamine biosynthetic pathway. This pathway responds to nutrient signals such as mTOR and transcription factors like ATF4, and feeds into glycoconjugate production. AMDHD2 acts downstream of GFPT1 and GNPNAT1 and influences UDP-GlcNAc pools, impacting N- and O-linked glycosylation. It requires a zinc cofactor and directly utilizes GlcNAc-6-P substrate. By deacetylating GlcNAc-6-P, AMDHD2 may regulate amino sugar flux, thereby controlling glycosylation modifications on cellular proteins.
In Jurkat T cells, AMDHD2 knockout likely disrupts hexosamine flux, altering UDP-GlcNAc availability and downstream glycosylation. Since glycosylation is critical for T-cell receptor function, immune synapse formation, and leukemia cell proliferation, this model enables study of how amino sugar metabolism impacts T-cell signaling and cancer biology. It provides a platform to examine metabolic dependencies in leukemic T lymphocytes and identify nodes linking glycosylation to immune cell fitness.
Applications include functional characterization of AMDHD2 by Western blot and RT-qPCR, glycosylation analysis via lectin blotting and flow cytometry, and metabolic profiling using metabolomics. Proliferation and apoptosis assays can assess growth phenotypes, while enzyme activity measurements confirm disruption of AMDHD2 catalytic function. This knockout system supports integrated studies of the hexosamine pathway in T-cell leukemia. For further inquiries, contact Ascent Research.
